CN112220920A - 一种重组新型冠状病毒疫苗组合物 - Google Patents
一种重组新型冠状病毒疫苗组合物 Download PDFInfo
- Publication number
- CN112220920A CN112220920A CN202011195131.1A CN202011195131A CN112220920A CN 112220920 A CN112220920 A CN 112220920A CN 202011195131 A CN202011195131 A CN 202011195131A CN 112220920 A CN112220920 A CN 112220920A
- Authority
- CN
- China
- Prior art keywords
- leu
- thr
- ser
- val
- asn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (8)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011195131.1A CN112220920B (zh) | 2020-10-30 | 2020-10-30 | 一种重组新型冠状病毒疫苗组合物 |
PCT/CN2021/124364 WO2022089233A1 (zh) | 2020-10-30 | 2021-10-18 | 重组刺突蛋白及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011195131.1A CN112220920B (zh) | 2020-10-30 | 2020-10-30 | 一种重组新型冠状病毒疫苗组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112220920A true CN112220920A (zh) | 2021-01-15 |
CN112220920B CN112220920B (zh) | 2023-06-13 |
Family
ID=74122616
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011195131.1A Active CN112220920B (zh) | 2020-10-30 | 2020-10-30 | 一种重组新型冠状病毒疫苗组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112220920B (zh) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113304257A (zh) * | 2021-04-15 | 2021-08-27 | 浙江天元生物药业有限公司 | 一种双佐剂新型冠状病毒灭活疫苗的制备方法及应用 |
CN113476600A (zh) * | 2021-07-09 | 2021-10-08 | 海南大学 | Avc-29作为疫苗佐剂的用途以及含有该佐剂的疫苗组合物 |
CN114316071A (zh) * | 2021-12-29 | 2022-04-12 | 浙江大学 | 一种重组腮腺炎病毒颗粒、组合物及其用途 |
WO2022089233A1 (zh) * | 2020-10-30 | 2022-05-05 | 上海泽润生物科技有限公司 | 重组刺突蛋白及其制备方法和用途 |
US11389528B2 (en) | 2020-06-10 | 2022-07-19 | Sichuan Clover Biopharmaceuticals, Inc | Coronavirus vaccine compositions, methods, and uses thereof |
CN115073565A (zh) * | 2022-06-13 | 2022-09-20 | 华素生物科技(北京)有限公司 | 重组新型冠状病毒s蛋白三聚体及其制备方法与应用 |
WO2022228560A1 (zh) * | 2021-04-30 | 2022-11-03 | 华普生物技术(江苏)股份有限公司 | 人工合成的含CpG单链脱氧寡核苷酸在疫苗中的应用 |
WO2022238689A1 (en) | 2021-05-11 | 2022-11-17 | Oxford Vacmedix UK Limited | Vaccine formulation comprising recombinant overlapping peptides and native prtoeins |
US11547673B1 (en) | 2020-04-22 | 2023-01-10 | BioNTech SE | Coronavirus vaccine |
WO2023165435A1 (zh) * | 2022-03-01 | 2023-09-07 | 上海泽润生物科技有限公司 | 重组刺突蛋白及其制备方法和用途 |
US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009085025A2 (en) * | 2007-06-19 | 2009-07-09 | Glaxosmithkline Biologicals S.A. | Vaccine |
CN111662389A (zh) * | 2020-06-05 | 2020-09-15 | 广州中医药大学(广州中医药研究院) | 一种SARS-CoV-2的融合蛋白及其疫苗组合物 |
CN111671890A (zh) * | 2020-05-14 | 2020-09-18 | 苏州大学 | 一种新型冠状病毒疫苗及其应用 |
-
2020
- 2020-10-30 CN CN202011195131.1A patent/CN112220920B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009085025A2 (en) * | 2007-06-19 | 2009-07-09 | Glaxosmithkline Biologicals S.A. | Vaccine |
CN111671890A (zh) * | 2020-05-14 | 2020-09-18 | 苏州大学 | 一种新型冠状病毒疫苗及其应用 |
CN111662389A (zh) * | 2020-06-05 | 2020-09-15 | 广州中医药大学(广州中医药研究院) | 一种SARS-CoV-2的融合蛋白及其疫苗组合物 |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11925694B2 (en) | 2020-04-22 | 2024-03-12 | BioNTech SE | Coronavirus vaccine |
US11547673B1 (en) | 2020-04-22 | 2023-01-10 | BioNTech SE | Coronavirus vaccine |
US11389528B2 (en) | 2020-06-10 | 2022-07-19 | Sichuan Clover Biopharmaceuticals, Inc | Coronavirus vaccine compositions, methods, and uses thereof |
WO2022089233A1 (zh) * | 2020-10-30 | 2022-05-05 | 上海泽润生物科技有限公司 | 重组刺突蛋白及其制备方法和用途 |
CN113304257A (zh) * | 2021-04-15 | 2021-08-27 | 浙江天元生物药业有限公司 | 一种双佐剂新型冠状病毒灭活疫苗的制备方法及应用 |
WO2022228560A1 (zh) * | 2021-04-30 | 2022-11-03 | 华普生物技术(江苏)股份有限公司 | 人工合成的含CpG单链脱氧寡核苷酸在疫苗中的应用 |
WO2022238689A1 (en) | 2021-05-11 | 2022-11-17 | Oxford Vacmedix UK Limited | Vaccine formulation comprising recombinant overlapping peptides and native prtoeins |
CN113476600B (zh) * | 2021-07-09 | 2023-05-30 | 海南大学 | Avc-29作为疫苗佐剂的用途以及含有该佐剂的疫苗组合物 |
CN113476600A (zh) * | 2021-07-09 | 2021-10-08 | 海南大学 | Avc-29作为疫苗佐剂的用途以及含有该佐剂的疫苗组合物 |
CN114316071A (zh) * | 2021-12-29 | 2022-04-12 | 浙江大学 | 一种重组腮腺炎病毒颗粒、组合物及其用途 |
CN114316071B (zh) * | 2021-12-29 | 2024-03-08 | 浙江大学 | 一种重组腮腺炎病毒颗粒、组合物及其用途 |
WO2023165435A1 (zh) * | 2022-03-01 | 2023-09-07 | 上海泽润生物科技有限公司 | 重组刺突蛋白及其制备方法和用途 |
CN115073565A (zh) * | 2022-06-13 | 2022-09-20 | 华素生物科技(北京)有限公司 | 重组新型冠状病毒s蛋白三聚体及其制备方法与应用 |
CN115073565B (zh) * | 2022-06-13 | 2023-02-21 | 华素生物科技(北京)有限公司 | 重组新型冠状病毒s蛋白三聚体及其制备方法与应用 |
US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
Also Published As
Publication number | Publication date |
---|---|
CN112220920B (zh) | 2023-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112220920B (zh) | 一种重组新型冠状病毒疫苗组合物 | |
Zhao et al. | Airway memory CD4+ T cells mediate protective immunity against emerging respiratory coronaviruses | |
KR101792684B1 (ko) | 불활성화된 치쿤구니야 바이러스 균주를 포함하는 백신 조성물 | |
AU2010249330B2 (en) | Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response | |
TWI620574B (zh) | 口蹄疫合成胜肽緊急疫苗 | |
KR102034234B1 (ko) | 대상포진 백신 조성물 | |
KR20220019846A (ko) | B형 간염 바이러스에 대한 백신 | |
ES2351489T3 (es) | Vacunas mejoradas. | |
CA3160755A1 (en) | Treatment of diseases related to hepatitis b virus | |
Olivera et al. | Protective cellular immune response against hepatitis C virus elicited by chimeric protein formulations in BALB/c mice | |
Guo et al. | A pathogen-like antigen-based vaccine confers immune protection against SARS-CoV-2 in non-human primates | |
Jin et al. | Induction of potent cellular immune response in mice by hepatitis C virus NS3 protein with double‐stranded RNA | |
Wang et al. | Immunization with recombinant Erns-LTB fusion protein elicits protective immune responses against bovine viral diarrhea virus | |
RU2748643C2 (ru) | Слитый белок | |
US20080085261A1 (en) | Vaccine Adjuvant | |
CN113248575B (zh) | 一种针对SARS-CoV-2的重组蛋白疫苗及其制备方法 | |
CA3222356A1 (en) | Compositions and methods to increase coronavirus immune response | |
WO2023023591A1 (en) | Development of mosaic vaccines against foot and mouth disease virus serotype o | |
EP2370100B1 (en) | Peptide adjuvants | |
KR20040022423A (ko) | 아쥬반트로서 제1형 ifn을 포함하는 백신 및 이와관련된 방법 | |
KR20230022160A (ko) | 사이토메갈로바이러스의 gB와 펜타머의 융합 단백질 및 당해 융합 단백질을 포함하는 백신 | |
WO2021216560A2 (en) | Vaccine compositions for sars-related coronaviruses and methods of use | |
Alvarez-Lajonchere et al. | Advances in DNA immunization against hepatitis C virus infection: Opportunities and challenges | |
Zhan et al. | Enhancement of humoral immunity in mice by coupling pUCpGs10 and aluminium to the HCV recombinant immunogen | |
TWI272104B (en) | Immunization against flavivirus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Liu Haitao Inventor after: Song Yujiao Inventor after: Li Jiadai Inventor after: Zhou Chenliang Inventor after: Zhang Lingli Inventor after: Liu Ge Inventor before: Liu Haitao Inventor before: Song Yujiao Inventor before: Li Jiadai Inventor before: Zhou Chenliang Inventor before: Zhang Lingli Inventor before: Liu Ge |
|
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |